First patient recruited today to the MATIS study for COVID-19 pneumonia! Nichola Cooper Nene Vergis #Letsdobetter New trial to test anti-inflammatory drugs in patients with COVID-19 pneumonia imperial.ac.uk/news/201993/ne…

Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results medrxiv.org/content/10.110… 🤔

We are delighted to be part of the MATIS trial team for treatments in COVID-19 pneumonia. It’s a new and welcome experience for efficient trial set up with rapid but careful reviews.

New research has shown the Oxford #COVID19 vaccine, which is administered in two doses, is 70.4% effective overall - or 90% effective if administered as a half dose then a full dose nihr.ac.uk/news/oxford-co…

Thanks to Dr. Fauci for coming by the NIH ICU to hear more about the patients on our study evaluating fostamatinib for hospitalized patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04… @TheBethesdaLabs NIH Clinical Center @NIHCritCare @nih_nhlbi @YogenKanthi @julieerbalvarez

Improvements in technology and overlapping clinical trials are among the reasons why COVID-19 vaccines are being developed quickly. Watch Deputy Chief Medical Officer Professor Jonathan Van-Tam describe in more detail how this saved time 👇

50th patient recruited to the MATIS study today! Congratulations to the study team! Nichola Cooper Nikhil Vergis Victoria Cornelius Rachel Phillips Melanie T Almonte 💙🐿📚🌱 Catherine Hockings asad charania

100 on the board now for MATIS and well past the halfway point. Well done and keep up the excellent work! Nichola Cooper Nikhil Vergis AlexMundell Victoria Cornelius Rachel Phillips Melanie T Almonte 💙🐿📚🌱 Catherine Hockings asad charania

A very warm welcome to Northwick Park which has now joined MATIS! Team effort AshWhittington Nikhil Vergis Catherine Hockings Nichola Cooper @rachelpips Andrew James Innes 💙💛 Melanie T Almonte 💙🐿📚🌱 Taryn Youngstein

Our Nichola Cooper is leading a study to evaluate the use of the drugs fostamatinib and ruxolitinib in patients with #COVID19 pneumonia. Be sure to follow MATIS to stay up to date with the latest findings, and visit our website for more info 👇 ow.ly/SBZ350DETMV

Meanwhile on the other side NEJM, two papers on the role of IL-6 inhibition in those hospitalised with COVID led locally by Nichola Cooper Taryn Youngstein and Anthony Gordon (bit.ly/3sHHApJ, bit.ly/3aYczI2)

$RIGL #news - Positive topline data shows #fostamatinib met the primary endpoint of safety in Phase 2 #clinicaltrial in hospitalized patients with #COVID19 - rigel.com/investors/news…

MATIS trial protocol published as a structured summary out now here: rdcu.be/cizOz AshWhittington Victoria Cornelius asad charania Nikhil Vergis Nichola Cooper @rachelpips Andrew James Innes 💙💛 Melanie T Almonte 💙🐿📚🌱 Taryn Youngstein